Chemistry:Oxogestone phenpropionate
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| Other names | Oxogesterone phenpropionate; Xinogestone; Oxageston; 20β-Hydroxy-19-norprogesterone phenylpropionate; 20β-Dihydro-19-norprogesterone 20β-(3-phenylpropionate); 20β-Hydroxy-19-norpregn-4-en-3-one 20β-(3-phenylpropionate); (20R)-3-Oxo-19-norpregn-4-en-20-yl 3-phenylpropanoate |
| Routes of administration | intramuscular injection |
| Drug class | Progestogen; Progestogen ester |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C29H38O3 |
| Molar mass | 434.620 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Oxogestone phenpropionate (OPP; USAN) (former developmental code name or tentative brand name Oxageston), also known as xinogestone, as well as 20β-hydroxy-19-norprogesterone 20β-(3-phenylpropionate), is a progestin related to the 19-norprogesterone derivatives which was developed as an injectable hormonal contraceptive, specifically a progestogen-only injectable contraceptive, in the 1960s and early 1970s but was never marketed.[1][2][3][4][5][6][7] It was studied at a dose of 50 to 75 mg once a month by intramuscular injection but was associated with a high failure rate with this regimen and was not further developed.[5] OPP is the 20β-(3-phenylpropionate) ester of oxogestone, which, similarly, was never marketed.[1]
See also
References
- ↑ 1.0 1.1 J. Elks (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 919–. ISBN 978-1-4757-2085-3. https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA919.
- ↑ George W.A Milne (8 May 2018). Drugs: Synonyms and Properties: Synonyms and Properties. Taylor & Francis. pp. 1577–. ISBN 978-1-351-78989-9. https://books.google.com/books?id=xUlaDwAAQBAJ&pg=PT1577.
- ↑ van der Vies, J. (1970). "Model studies in vitro with long-acting hormonal preparations". Acta Endocrinologica 64 (4): 656–669. doi:10.1530/acta.0.0640656. ISSN 0804-4643. PMID 5468664.
- ↑ Heeres, S. G. (1967). Preliminary results with a long-acting progestational preparation. In: Wood, C. and Walters, W.A., eds. Fifth World Congress of Gynaecology and Obstetrics, Sydney, September 1967. New York Appleton-Century-Crofts, 1967. p. 348 http://www.popline.org/node/475027
- ↑ 5.0 5.1 "The clinical use of monthly injectable contraceptive preparations". Obstet Gynecol Surv 32 (6): 335–47. June 1977. doi:10.1097/00006254-197706000-00001. PMID 865726.
- ↑ "The contraceptive progestagens". Chem. Rev. 70 (6): 713–26. 1970. doi:10.1021/cr60268a004. PMID 4098492.
- ↑ Mokhtar K. Toppozada (1983). "Monthly Injectable Contraceptives". Long-Acting Contraception. pp. 93–103. OCLC 35018604. https://scholar.google.com/scholar?cluster=14664537528797672080.
 |  |
